Compare Snowflake Inc (SNOW) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Snowflake Inc vs Viatris Inc — how do they compare? Snowflake Inc trades at $271.7 (market cap $95.09B), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Snowflake Inc is far larger — about 4.8× Viatris Inc's market cap, and Viatris Inc pays a 2.83% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals.
| SNOW | VTRS | |
|---|---|---|
Market Cap | $95.09B | $19.79B |
Sector | Technology | Health |
52-Week High | $280.16 | $17.39 |
52-Week Low | $121.11 | $8.74 |
Enterprise Value | $94.90B | $32.00B |
Dividend Yield | — | 2.83% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
